> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncologic Panel Meeting to Review Ukoniq sNDA
- URL: https://www.fdaweb.com/oncologic-panel-meeting-to-review-ukoniq-snda/
- Published: 2022-03-10T12:00:00.000Z
- Updated: 2026-09-14T17:36:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151338

*Federal Register* notice: FDA has announced a 4/21-22 Oncologic Drugs Advisory Committee meeting. On 4/21, the panel will discuss the appropriate approach for phosphatidylinositol-3-kinase inhibitors currently under development for use in patients with hematologic malignancies and whether randomized data should be required to support a demonstration of substantial evidence of effectiveness. On 4/22, the committee will discuss a TG Therapeutics supplemental NDA for Ukoniq (umbralisib) tablets, and its BLA for ublituximab injection — both submitted for combination use in treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. In addition, it will discuss the existing umbralisib accelerated approval indications in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-03-10/pdf/2022-05022.pdf?ref=fdaweb.com).